Witan Investment Trust plc Review of performance measurement benchmark

Witan Investment Trust plc

Witan Investment Trust plc (LON: WTAN) has reviewed its performance benchmark and announced today that the following benchmark will take effect from January 2020:

UK (FTSE All Share Index) 15% (previously 30%)

Global (FTSE All World Index) 85% (previously 70% in fixed percentages of four international indices)

The Company’s benchmark, which is used as a reference point for comparing performance, has evolved over time to reflect changes in the investment universe from which most of the portfolio holdings are chosen.

The separate UK benchmark component, which has reduced in three stages from 60% in 2004 to the current level of 30%, will be 15% from 2020. The effective UK benchmark content will be c 19% since, in addition to the specified 15% in the UK, the global index has a 5% weighting in the UK.

The second change taking effect from 2020 is a simplification of the overseas element of the benchmark to a single index (the FTSE All World Index) from the previous composite benchmark. This is intended to make it easier for investors to monitor.

The Company’s portfolio is not designed to track any index or combination of market indices. It is actively managed, with decisions on investment being distinct from the benchmark used for performance comparison. The Company’s managers invest in companies on the basis of their shares’ potential to deliver above-average returns and to outperform market indices. The Company’s portfolio will continue to differ materially, at the stock, sector and geographical level from the composition of the benchmark.

Witan Investment Trust plc believes that the new benchmark is more reflective of the range of opportunities in the global economy and that shareholders will benefit in the long-term from exposure to a more international investment universe. The Company’s investment objective of delivering long-term growth in income and capital remains unchanged.

Share on:
Find more news, interviews, share price & company profile here for:

    Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

    Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis.

    Dekel Agri-Vision sees record cashew output, higher palm oil prices

    Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024.

    Diversified Energy delivers strong H1 2025 with Carlyle partnership boost

    Diversified Energy Company posted first-half 2025 results in line with expectations, delivering strong production growth, improved financial metrics, and $152 million in adjusted free cash flow

    EDX Medical Group to complete the development of new pneumonia test

    EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

    Union Jack Oil director increases shareholding

    Union Jack Oil Non-Executive Director Craig Howie has acquired 122,000 shares at 5.075 pence each, raising his total holding to 3,377,000 shares, representing 2.21% of the company’s issued share capital.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search